Reports › Company profiles › Lupin Limited
Lupin Limited
Sector: Pharmaceuticals | HQ: Mumbai, Maharashtra | Founded: 1968 | Employees: ~22,000
Listed as: NSE / BSE listed | NSE / BSE | Ticker: LUPIN.NS | Website →
Live stock price (NSE)
₹2,256
-123.60 (-5.19%) today
Source: Yahoo Finance · Refreshed every 15 minutes · Fetched 11/5/2026, 4:34:39 pm IST. For information only; not investment advice.
Key people
- Vinita Gupta (CEO)
- Nilesh Gupta (Managing Director)
Company overview
Lupin Limited is one of India's top-5 pharmaceutical companies. Founded in 1968 in Mumbai, Lupin operates 14 manufacturing facilities globally. FY25 revenue was approximately ₹21,500 crore. Lupin has a meaningful US generics business, a strong India domestic franchise, and an emerging biosimilars and specialty portfolio.
Business model
India domestic, US generics, Emerging Markets, EMEA, and API (sold through Lupin Atharv Ability).
Operating segments
India Domestic
Cardiovascular, anti-diabetic, anti-asthmatic chronic-therapy franchises.
US Generics
Recent complex-generic launches in respiratory and immunology.
Emerging Markets
Brazil, Mexico, Russia, Australia, Philippines.
EMEA
UK, Germany, France generics and OTC.
Biosimilars
Etanercept biosimilar, others in pipeline.
Financial performance and recent trajectory
Lupin FY25 revenue ₹21,500 crore with EBITDA margin recovering to 19-21 percent from FY22 lows. The Gupta family is the founding promoter group.
Stock performance and shareholder context
Lupin (NSE: LUPIN, BSE: 500257). Promoter holding approximately 47 percent.
12-month price trajectory
Monthly closes over the last 12 months. Source: Yahoo Finance.
Competitive position
Top-5 Indian pharma. Strong India domestic (5-6 percent IPM share). Growing complex-generic and biosimilar pipeline.
Key risks
US FDA inspection; complex-generic competition; biosimilar pipeline execution.
Outlook
Specialty branded launches and biosimilars are the key catalysts through FY28.
KAMRIT point of view
Building or competing with Lupin?
KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Lupin and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.
Related KAMRIT project reports
These reports use Lupin Limited in benchmarking and competitive analysis sections.
Pharmaceutical Formulations Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹4.5 lakh crore · CAGR 11.8%
API / Bulk Drug Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹2.2 lakh crore · CAGR 13.8%
Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.